- On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hyftor, intended for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and paediatric patients aged 6 years and older.
Contribute to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices.
About Plusultra Pharma
As a research and development-based pharmaceutical company, we develop pharmaceuticals for unmet needs, such as orphan drugs, off-label medicines, and paediatric medicines. Before delivering new products, we always consider the needs of our customers.
Plusultra pharma, as a group of Nobelpharma, has earnestly addressed the launch of medicines that other companies do not pursue, in order to fulfil the needs of society.
“Critical but neglected – That is precisely why it must be created.”
Plusultra pharma GmbH and Plusultra pharma UK Ltd. were established in Duesseldorf, Germany, and Oxford, United Kingdom, respectively in 2020, as overseas subsidiaries in Europa regions of Nobelpharma Group. The headquarter of the group, Nobelpharma was founded in 2003 in Tokyo, Japan, to fulfill our mission of “Contributing to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices” that other companies do not pursue. We have since obtained approvals for the manufacturing and sale of new drugs in numbers on par with large pharmaceutical companies, and we have been providing these drugs to patients. We take much pride in the unique corporate philosophy that has made this possible.